首页> 外文OA文献 >Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates
【2h】

Biological treatment of the knee with platelet-rich plasma or bone marrow aspirate concentrates

机译:用富含血小板的血浆或骨髓抽吸浓缩物对膝盖进行生物治疗

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Knee pathologies including focal cartilage injuries, osteoarthritis (OA), and ligament injuries are common. The poor regeneration and healing potential of cartilage has led to the search for other treatment modalities with improved healing capacity. Furthermore, with an increasing elderly population that desires to remain active, the burden of knee pathologies is expected to increase. Increased sports participation and the desire to return to activities faster is also demanding more effective and minimally invasive treatment options. Thus, the use of biologic agents in the treatment of knee pathologies has emerged as a potential option. Despite the increasing use of biologic agents for knee pathology, there are conflicting results on the efficacy of these products. Furthermore, strong data supporting the optimal preparation methods and composition for widely used biologic agents, such as platelet-rich plasma (PRP) and bone marrow aspirate concentrate (BMAC), largely remain absent from the literature. This review presents the literature on the most commonly employed biologic agents for the different knee pathologies.
机译:膝关节病变包括关节软骨损伤,骨关节炎(OA)和韧带损伤很常见。软骨再生和愈合能力差,导致人们寻求其他具有改善愈合能力的治疗方式。此外,随着希望保持活跃的老年人口的增加,预计膝部疾病的负担会增加。越来越多的体育参与以及渴望更快地恢复活动的愿望也要求更有效和微创的治疗选择。因此,在膝盖疾病的治疗中使用生物制剂已成为一种潜在的选择。尽管越来越多地将生物制剂用于膝关节病理学,但这些产品的功效却存在矛盾的结果。此外,文献中仍然缺少支持广泛使用的生物制剂(例如富血小板血浆(PRP)和骨髓抽吸浓缩液(BMAC))的最佳制备方法和组成的强大数据。这篇综述介绍了有关不同膝关节病变的最常用生物制剂的文献。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号